{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Non-Hodgkin+Lymphoma+%28B-NHL%29&page=12",
    "query": {
      "condition": "B-cell Non-Hodgkin Lymphoma (B-NHL)",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 1092,
    "total_pages": 110,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Non-Hodgkin+Lymphoma+%28B-NHL%29&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Non-Hodgkin+Lymphoma+%28B-NHL%29&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T04:19:51.018Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00105001",
      "title": "Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable",
        "Previously Treated Myelodysplastic Syndrome",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Plasma Cell Myeloma",
        "Waldenstrom Macroglobulinemia",
        "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Adult Acute Lymphoblastic Leukemia in Remission",
        "Adult Acute Myeloid Leukemia in Remission",
        "Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11",
        "Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1",
        "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative",
        "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Childhood Acute Lymphoblastic Leukemia in Remission",
        "Childhood Acute Myeloid Leukemia in Remission",
        "Childhood Burkitt Lymphoma",
        "Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Childhood Diffuse Large Cell Lymphoma",
        "Childhood Immunoblastic Lymphoma",
        "Childhood Myelodysplastic Syndrome",
        "Stage II Contiguous Adult Burkitt Lymphoma",
        "Stage II Contiguous Adult Diffuse Large Cell Lymphoma",
        "Stage II Contiguous Adult Diffuse Mixed Cell Lymphoma",
        "Stage II Contiguous Adult Diffuse Small Cleaved Cell Lymphoma",
        "Stage II Adult Contiguous Immunoblastic Lymphoma",
        "Stage II Contiguous Adult Lymphoblastic Lymphoma",
        "Stage II Grade 1 Contiguous Follicular Lymphoma",
        "Stage II Grade 2 Contiguous Follicular Lymphoma",
        "Stage II Grade 3 Contiguous Follicular Lymphoma",
        "Stage II Contiguous Mantle Cell Lymphoma",
        "Stage II Non-Contiguous Adult Burkitt Lymphoma",
        "Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma",
        "Stage II Non-Contiguous Adult Diffuse Mixed Cell Lymphoma",
        "Stage II Non-Contiguous Adult Diffuse Small Cleaved Cell Lymphoma",
        "Stage II Adult Non-Contiguous Immunoblastic Lymphoma",
        "Stage II Non-Contiguous Adult Lymphoblastic Lymphoma",
        "Stage II Grade 1 Non-Contiguous Follicular Lymphoma",
        "Stage II Grade 2 Non-Contiguous Follicular Lymphoma",
        "Stage II Grade 3 Non-Contiguous Follicular Lymphoma",
        "Stage II Non-Contiguous Mantle Cell Lymphoma",
        "Stage II Small Lymphocytic Lymphoma",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Adult Hodgkin Lymphoma",
        "Recurrent Adult Immunoblastic Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Recurrent Childhood Anaplastic Large Cell Lymphoma",
        "Recurrent Childhood Large Cell Lymphoma",
        "Recurrent Childhood Lymphoblastic Lymphoma",
        "Recurrent Childhood Burkitt Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Recurrent Childhood Hodgkin Lymphoma",
        "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Secondary Myelodysplastic Syndrome",
        "Stage I Adult Burkitt Lymphoma",
        "Stage I Adult Diffuse Large Cell Lymphoma",
        "Stage I Adult Diffuse Mixed Cell Lymphoma",
        "Stage I Adult Immunoblastic Lymphoma",
        "Stage I Adult Lymphoblastic Lymphoma",
        "Stage I Childhood Anaplastic Large Cell Lymphoma",
        "Stage I Childhood Large Cell Lymphoma",
        "Stage I Childhood Lymphoblastic Lymphoma",
        "Stage I Childhood Burkitt Lymphoma",
        "Stage I Grade 1 Follicular Lymphoma",
        "Stage I Grade 2 Follicular Lymphoma",
        "Stage I Grade 3 Follicular Lymphoma",
        "Stage I Mantle Cell Lymphoma",
        "Stage I Marginal Zone Lymphoma",
        "Stage I Small Lymphocytic Lymphoma",
        "Stage II Childhood Anaplastic Large Cell Lymphoma",
        "Stage II Childhood Lymphoblastic Lymphoma",
        "Stage II Childhood Burkitt Lymphoma",
        "Stage III Adult Burkitt Lymphoma",
        "Stage III Adult Diffuse Large Cell Lymphoma",
        "Stage III Adult Diffuse Mixed Cell Lymphoma",
        "Stage III Adult Diffuse Small Cleaved Cell Lymphoma",
        "Stage III Adult Immunoblastic Lymphoma",
        "Stage III Adult Lymphoblastic Lymphoma",
        "Stage III Childhood Anaplastic Large Cell Lymphoma",
        "Stage III Childhood Large Cell Lymphoma",
        "Stage III Childhood Lymphoblastic Lymphoma",
        "Stage III Childhood Burkitt Lymphoma",
        "Stage III Grade 1 Follicular Lymphoma",
        "Stage III Grade 2 Follicular Lymphoma",
        "Stage III Grade 3 Follicular Lymphoma",
        "Stage III Mantle Cell Lymphoma",
        "Stage III Marginal Zone Lymphoma",
        "Stage III Small Lymphocytic Lymphoma",
        "Stage IV Adult Burkitt Lymphoma",
        "Stage IV Adult Diffuse Large Cell Lymphoma",
        "Stage IV Adult Diffuse Mixed Cell Lymphoma",
        "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma",
        "Stage IV Adult Immunoblastic Lymphoma",
        "Stage IV Adult Lymphoblastic Lymphoma",
        "Stage IV Childhood Anaplastic Large Cell Lymphoma",
        "Stage IV Childhood Large Cell Lymphoma",
        "Stage IV Childhood Lymphoblastic Lymphoma",
        "Stage IV Childhood Burkitt Lymphoma",
        "Stage IV Grade 1 Follicular Lymphoma",
        "Stage IV Grade 2 Follicular Lymphoma",
        "Stage IV Grade 3 Follicular Lymphoma",
        "Stage IV Mantle Cell Lymphoma",
        "Stage IV Marginal Zone Lymphoma",
        "Stage IV Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 210,
      "start_date": "2004-11",
      "completion_date": "2015-05-08",
      "has_results": true,
      "last_update_posted_date": "2019-10-30",
      "last_synced_at": "2026-10-14T04:19:51.018Z",
      "location_count": 7,
      "location_summary": "Denver, Colorado • Atlanta, Georgia • Salt Lake City, Utah + 2 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00105001"
    },
    {
      "nct_id": "NCT03615105",
      "title": "Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoid Leukemia (ALL)",
        "Acute Myeloid Leukemia (AML)",
        "Chronic Myeloid Leukemia (CML)",
        "Hodgkin Lymphoma",
        "Non-Hodgkin Lymphoma",
        "Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Hyperfractionated total body irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Clofarabine",
          "type": "DRUG"
        },
        {
          "name": "HPC(A) stem cell allograft",
          "type": "PROCEDURE"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Rabbit antithymocyte globulin",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "PROCEDURE",
        "DEVICE"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "Up to 65 Years"
      },
      "enrollment_count": 9,
      "start_date": "2018-07-25",
      "completion_date": "2024-03-06",
      "has_results": true,
      "last_update_posted_date": "2025-04-06",
      "last_synced_at": "2026-10-14T04:19:51.018Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03615105"
    },
    {
      "nct_id": "NCT01232556",
      "title": "A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin"
      ],
      "interventions": [
        {
          "name": "Inotuzumab ozogamicin",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "rituximab + gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "rituximab +bendamustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 338,
      "start_date": "2011-04-04",
      "completion_date": "2014-03-28",
      "has_results": true,
      "last_update_posted_date": "2019-01-08",
      "last_synced_at": "2026-10-14T04:19:51.018Z",
      "location_count": 82,
      "location_summary": "Burbank, California • Fresno, California • Los Angeles, California + 42 more",
      "locations": [
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01232556"
    },
    {
      "nct_id": "NCT03488251",
      "title": "PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-hodgkin Lymphoma,B Cell",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Relapsed Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "MT-3724",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Molecular Templates, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2018-08-20",
      "completion_date": "2021-03-12",
      "has_results": true,
      "last_update_posted_date": "2022-08-16",
      "last_synced_at": "2026-10-14T04:19:51.018Z",
      "location_count": 9,
      "location_summary": "Orange, California • Santa Monica, California • Whittier, California + 6 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03488251"
    },
    {
      "nct_id": "NCT00474929",
      "title": "Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "RAD001",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 103,
      "start_date": "2007-08-29",
      "completion_date": "2019-08-08",
      "has_results": true,
      "last_update_posted_date": "2019-08-20",
      "last_synced_at": "2026-10-14T04:19:51.018Z",
      "location_count": 2,
      "location_summary": "Iowa City, Iowa • Rochester, Minnesota",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00474929"
    },
    {
      "nct_id": "NCT01695941",
      "title": "Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent B-Cell Non-Hodgkin Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Refractory B-Cell Non-Hodgkin Lymphoma",
        "Refractory Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Alisertib",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2012-08-31",
      "completion_date": "2027-03-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-10-14T04:19:51.018Z",
      "location_count": 4,
      "location_summary": "New York, New York • The Bronx, New York • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01695941"
    },
    {
      "nct_id": "NCT00416312",
      "title": "Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Patient-specific dosimetry",
          "type": "DEVICE"
        },
        {
          "name": "conventional dosimetry",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 9,
      "start_date": "2006-07",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2018-08-27",
      "last_synced_at": "2026-10-14T04:19:51.018Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00416312"
    },
    {
      "nct_id": "NCT05389423",
      "title": "Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Large Cell Lymphoma",
        "Non-Hodgkin Lymphoma",
        "Burkitt Lymphoma",
        "Plasmablastic Lymphoma",
        "B-Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 25,
      "start_date": "2023-06-27",
      "completion_date": "2032-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-10-14T04:19:51.018Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05389423"
    },
    {
      "nct_id": "NCT03842696",
      "title": "Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hematologic Diseases",
        "Acute Leukemia in Remission",
        "Chronic Myelogenous Leukemia - Chronic Phase",
        "Chronic Myelogenous Leukemia, Accelerated Phase",
        "Chronic Myelogenous Leukemia, Blastic Phase",
        "Myelodysplastic Syndromes",
        "Mantle Cell Lymphoma",
        "Follicular Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Non Hodgkin Lymphoma",
        "Graft Vs Host Disease",
        "Graft-versus-host-disease"
      ],
      "interventions": [
        {
          "name": "Vorinostat",
          "type": "DRUG"
        },
        {
          "name": "Blood and Marrow Transplant (BMT)",
          "type": "PROCEDURE"
        },
        {
          "name": "Tacrolimus (or cyclosporine)",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil (MMF)",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "3 Years to 39 Years"
      },
      "enrollment_count": 43,
      "start_date": "2020-02-04",
      "completion_date": "2026-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-27",
      "last_synced_at": "2026-10-14T04:19:51.018Z",
      "location_count": 7,
      "location_summary": "Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 4 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03842696"
    },
    {
      "nct_id": "NCT00053196",
      "title": "Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma",
        "Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myeloproliferative Neoplasms"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "G-CSF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "allogeneic cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "allopurinol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "Up to 69 Years"
      },
      "enrollment_count": 82,
      "start_date": "2002-12",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2016-07-01",
      "last_synced_at": "2026-10-14T04:19:51.018Z",
      "location_count": 12,
      "location_summary": "La Jolla, California • Lewes, Delaware • Newark, Delaware + 9 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Lewes",
          "state": "Delaware"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Elkton MD",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00053196"
    }
  ]
}